Detalhe da pesquisa
1.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Blood
; 143(3): 258-271, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879074
2.
DLBCL: Who is high risk and how should treatment be optimized?
Blood
; 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37922443
3.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369099
4.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Blood
; 142(26): 2327-2331, 2023 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738563
5.
Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235513
6.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Am J Hematol
; 99(3): 408-421, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38217361
7.
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 28(3): 199-207, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648324
8.
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
Hematol Oncol
; 41(1): 39-49, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36305717
9.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171597
10.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Am J Hematol
; 98(3): 464-471, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36629030
11.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol
; 98(2): 300-308, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588409
12.
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
Blood
; 135(13): 1008-1018, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977005
13.
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018).
Am J Hematol
; 97(9): 1150-1158, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713565
14.
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Curr Treat Options Oncol
; 23(2): 155-170, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182296
15.
Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma.
Int J Cancer
; 149(3): 535-545, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33644854
16.
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
Br J Haematol
; 195(2): 210-216, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340248
17.
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.
Blood
; 134(16): 1289-1297, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350266
18.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Hematol Oncol
; 39(5): 658-663, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453851
19.
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
Am J Hematol
; 96(8): 979-988, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971040
20.
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
Am J Hematol
; 96(8): 945-953, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909933